109 related articles for article (PubMed ID: 22021681)
1. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of griseofulvin against multiple myeloma.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
[TBL] [Abstract][Full Text] [Related]
3. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
5. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(1):99-103. PubMed ID: 21282741
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
7. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.
Schmidt M; Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(3):325-33. PubMed ID: 21576405
[TBL] [Abstract][Full Text] [Related]
8. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
9. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
Schmeel FC; Schmeel LC; Kim Y; Schmidt-Wolf IG
Hematol Oncol; 2014 Dec; 32(4):197-204. PubMed ID: 24470348
[TBL] [Abstract][Full Text] [Related]
10. Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC.
Yang F; Zeng Q; Yu G; Li S; Wang CY
Cell Signal; 2006 May; 18(5):679-87. PubMed ID: 16084063
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.
Schmeel LC; Schmeel FC; Blaum-Feder S; Schmidt-Wolf IG
Anticancer Res; 2015 Nov; 35(11):5921-6. PubMed ID: 26504016
[TBL] [Abstract][Full Text] [Related]
12. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
13. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
Shan BE; Wang MX; Li RQ
Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
[TBL] [Abstract][Full Text] [Related]
14. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Song S; Christova T; Perusini S; Alizadeh S; Bao RY; Miller BW; Hurren R; Jitkova Y; Gronda M; Isaac M; Joseph B; Subramaniam R; Aman A; Chau A; Hogge DE; Weir SJ; Kasper J; Schimmer AD; Al-awar R; Wrana JL; Attisano L
Cancer Res; 2011 Dec; 71(24):7628-39. PubMed ID: 22009536
[TBL] [Abstract][Full Text] [Related]
15. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
Ashihara E; Kawata E; Nakagawa Y; Shimazaski C; Kuroda J; Taniguchi K; Uchiyama H; Tanaka R; Yokota A; Takeuchi M; Kamitsuji Y; Inaba T; Taniwaki M; Kimura S; Maekawa T
Clin Cancer Res; 2009 Apr; 15(8):2731-8. PubMed ID: 19351774
[TBL] [Abstract][Full Text] [Related]
16. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.
Yang W; Yan HX; Chen L; Liu Q; He YQ; Yu LX; Zhang SH; Huang DD; Tang L; Kong XN; Chen C; Liu SQ; Wu MC; Wang HY
Cancer Res; 2008 Jun; 68(11):4287-95. PubMed ID: 18519688
[TBL] [Abstract][Full Text] [Related]
17. Differentiation-inducing factor-1 alters canonical Wnt signaling and suppresses alkaline phosphatase expression in osteoblast-like cell lines.
Matsuzaki E; Takahashi-Yanaga F; Miwa Y; Hirata M; Watanabe Y; Sato N; Morimoto S; Hirofuji T; Maeda K; Sasaguri T
J Bone Miner Res; 2006 Aug; 21(8):1307-16. PubMed ID: 16869729
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Wnt/beta-catenin pathway in renal cell carcinoma.
Von Schulz-Hausmann SA; Schmeel LC; Schmeel FC; Schmidt-Wolf IG
Anticancer Res; 2014 Aug; 34(8):4101-8. PubMed ID: 25075035
[TBL] [Abstract][Full Text] [Related]
19. Influencing the Wnt signaling pathway in multiple myeloma.
Kim Y; Reifenberger G; Lu D; Endo T; Carson DA; Gast SM; Meschenmoser K; Nowak M; Schmidt-Wolf IG
Anticancer Res; 2011 Feb; 31(2):725-30. PubMed ID: 21378363
[TBL] [Abstract][Full Text] [Related]
20. Targeting Wnt pathway in lymphoma and myeloma cells.
Schmidt M; Sievers E; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
[No Abstract] [Full Text] [Related]
[Next] [New Search]